<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1556">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869817</url>
  </required_header>
  <id_info>
    <org_study_id>IA0147</org_study_id>
    <secondary_id>U19AG032438</secondary_id>
    <secondary_id>UF1AG032438</secondary_id>
    <nct_id>NCT00869817</nct_id>
  </id_info>
  <brief_title>Dominantly Inherited Alzheimer Network (DIAN)</brief_title>
  <acronym>DIAN</acronym>
  <official_title>Dominantly Inherited Alzheimer Network (DIAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify potential biomarkers that may predict the&#xD;
      development of Alzheimer's disease in people who carry an Alzheimer's mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and&#xD;
      is an important model for study because the responsible mutations have known biochemical&#xD;
      consequences that are believed to underlie the pathological basis of the disorder. Three&#xD;
      major hypotheses will be tested:&#xD;
&#xD;
        -  First, that there is a period of preclinical (presymptomatic) AD in individuals who are&#xD;
           destined to develop early-onset dementia (gene carriers) that can be detected by changes&#xD;
           in biological fluids and in neuroimaging correlates in comparison with individuals who&#xD;
           will not develop early-onset dementia (non-carriers).&#xD;
&#xD;
        -  Second, because all identified causative mutations for AD affect the normal processing&#xD;
           of amyloid precursor protein (APP) and increase brain levels of amyloid-beta 42 (Aβ42),&#xD;
           the sequence of preclinical changes initially will involve Aβ42 (production and&#xD;
           clearance; reduced levels in cerebrospinal fluid [CSF]), followed by evidence for&#xD;
           cerebral deposition of Aβ42 (amyloid imaging), followed by cerebral metabolic activity&#xD;
           (functional imaging), and finally by regional atrophy (structural imaging).&#xD;
&#xD;
        -  Finally, that the phenotype of symptomatic early-onset familial AD, including its&#xD;
           clinical course, is similar to that of late-onset &quot;sporadic&quot; AD.&#xD;
&#xD;
      The following specific aims will be used to test these hypotheses:&#xD;
&#xD;
        1. Maintain the established international DIAN registry of individuals (MCs and&#xD;
           non-carriers (NC), symptomatic and asymptomatic) who are biological adult children of an&#xD;
           affected parent with an APP, PSEN1, or PSEN2 mutation causing AD and assess participants&#xD;
           every 2 years with the uniform DIAN protocol.&#xD;
&#xD;
        2. Recruit to the registry 50 new asymptomatic participants, both MCs and NCs, in Year 1 of&#xD;
           the next budget period to maintain the total DIAN cohort at ~250 individuals. These new&#xD;
           participants will include those who are more than 15 years younger than the estimated&#xD;
           age of symptomatic onset (EAO) to explore the earliest observable biomarker changes of&#xD;
           preclinical AD.&#xD;
&#xD;
        3. Maintain the integrated DIAN database and biospecimen repository to disseminate data and&#xD;
           tissue to qualified investigators (within and outside of DIAN) in a user-friendly manner&#xD;
           and to permit analyses within, between, and among the various data domains that will&#xD;
           include:&#xD;
&#xD;
             1. In asymptomatic MCs (using NCs as controls), determine the temporal ordering and&#xD;
                rate of intraindividual change in clinical, cognitive, imaging, and fluid&#xD;
                biomarkers of AD prior to EAO&#xD;
&#xD;
             2. In symptomatic MCs, compare the clinical and neuropathological phenotypes of ADAD&#xD;
                to those of LOAD, using datasets such as ADNI.&#xD;
&#xD;
        4. Utilize the DIAN cohort and its database and biospecimen repository to support new&#xD;
           scientific studies, including use of exome chip technology to examine potential&#xD;
           modifiers of age at symptomatic onset. Pursue other new scientific initiatives that are&#xD;
           funded independently of the DIAN grant but are conducted within the DIAN infrastructure&#xD;
           at no cost to DIAN including: Dermal fibroblasts and induced pluripotent stem cells&#xD;
           (iPSCs), examine biomarker surrogates for neurogeneration in CSF including Visinin-like&#xD;
           protein-1 (VILIP-1), Tau seeding assay, Stable Isotope Leucine Kinetics (SILK) in DIAN&#xD;
           participants, determine the exact Abeta species that underlie AD pathology using Mass&#xD;
           spectrometry, exome sequencing on all DIAN participants to search for both positive and&#xD;
           negative modifiers of EYO, and amyloid imaging crossover to [18F]florbetapir.&#xD;
&#xD;
        5. Provide genetic counseling to any and all DIAN participants who wish to learn their&#xD;
           mutation status and, for those who decide to learn their status after counseling,&#xD;
           provide genetic testing by Clinical Laboratory Improvement Amendments (CLIA)-approved&#xD;
           laboratories (i.e., outside of DIAN).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Positive predictive power of a biomarker or group of biomarkers</measure>
    <time_frame>Variable follow-up assessment based on age in relation to age at onset of affected parent.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging</measure>
    <time_frame>Variable follow-up assessment based on age in relation to age at onset of affected parent</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical markers also examined from clinical interview and cognitive testing</measure>
    <time_frame>Variable follow-up assessment based on age in relation to age at onset of affected parent</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Mutation Positive</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Mutation Negative</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      buffy coat, plasma, cerebral spinal fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Mutation carriers and non-carriers from families with a mutation (which is different from&#xD;
        the genetic risk factor Apo-E4) known to cause Alzheimer's disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained from participant and collateral source prior to any&#xD;
             study-related procedures.&#xD;
&#xD;
          -  Aged 18 (inclusive) or older and the child of an affected individual (clinically or by&#xD;
             testing) in a pedigree with a known mutation for ADAD.&#xD;
&#xD;
          -  Cognitively normal. Primary enrollment will focus on recruitment of asymptomatic adult&#xD;
             children who are more than 15 years younger than the estimated age of symptom onset.&#xD;
             Enrollment of new participants with very mild, mild, or moderate cognitive impairment&#xD;
             is allowed with the prior approval of the DIAN Coordinating Center.&#xD;
&#xD;
          -  Has two persons who are not their full-blooded siblings who can serve as collateral&#xD;
             sources for the study.&#xD;
&#xD;
          -  Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade&#xD;
             level (international equivalent) or above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under age 18&#xD;
&#xD;
          -  Medical or psychiatric illness that would interfere in completing initial and&#xD;
             follow-up visits&#xD;
&#xD;
          -  Requires nursing home level care&#xD;
&#xD;
          -  Has no one who can serve as a study informant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J. Bateman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alisha Daniels, MD,MHA</last_name>
    <role>Study Director</role>
    <affiliation>(314) 273-9057</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alisha Daniels, MD,MHA</last_name>
    <phone>(314) 273-9057</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>DIAN Obs Admin Core</last_name>
    <email>NEURO-DIANCoordinatingCenter@email.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Graham</last_name>
      <phone>904-953-4329</phone>
      <email>graham.morgan@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory S Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University-Indiana Alzheimer Disease Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Buck, RN</last_name>
      <phone>317-963-1847</phone>
      <email>jilmbuck@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Bernardino Ghetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Fitzpatrick, MS</last_name>
      <phone>617-643-5200</phone>
      <email>cdfitzpatrick@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Jasmeer Chhatwal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Sigurdson, RN, MPH</last_name>
      <phone>314-362-2256</phone>
      <email>sigurdsonw@neuro.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tamara Donahue, RN, MS</last_name>
      <phone>314-362-2147</phone>
      <email>donahuet@neuro.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Randall Bateman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlene Mejia</last_name>
      <phone>212-305-9168</phone>
      <email>AM4717@CUMC.COLUMBIA.EDU</email>
    </contact>
    <investigator>
      <last_name>James Noble, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zana Ikonomovic, MD</last_name>
      <phone>412-692-2740</phone>
      <email>ikonomovics@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Sarah Berman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Bodge, PhD</last_name>
      <phone>401-455-6403</phone>
      <email>cbodge@butler.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Salloway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia&quot; (FLENI) Instituto de Investigaciones Neurológicas Raúl Correa</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricio Chrem, MD</last_name>
      <phone>20565342</phone>
      <email>pchremmendez@fleni.org.ar</email>
    </contact>
    <investigator>
      <last_name>Ricardo Allegri, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuroscience Research Australia</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William S. Brooks, MBBS, MPH</last_name>
      <phone>+612 9399 1101</phone>
      <email>w.brooks@NeuRA.edu.au</email>
    </contact>
    <investigator>
      <last_name>Peter Schofield, PhD, DSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mental Health Research Institute, University of Melbourne</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3130</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Sir James McCusker Alzheimer's Disease Research Unit, Edith Cowan University</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Taddei</last_name>
      <phone>+61-(0)8-6304-5107</phone>
      <email>k.taddei@ecu.edu.au</email>
    </contact>
    <investigator>
      <last_name>Ralph Martins, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maira Okada de Oliveira</last_name>
      <email>maira.okada@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Leonel Tadao Takada, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Research Centre for Studies in Aging</name>
      <address>
        <city>Verdun</city>
        <state>Quebec</state>
        <zip>H4H 1R3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamar Tatigian</last_name>
      <email>tamar.tatigian@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Serge Gauthier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grupo Neurociencias de Antioquia</name>
      <address>
        <city>Medellín</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yudy Milena León Varela</last_name>
      <email>yudy.leon@gna.org.co</email>
    </contact>
    <investigator>
      <last_name>Franciso Lopera Restrepo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Center for Neurodegenerative Diseases (DZNE) Munich, and University Hospital Ludwig-Maximilians-Universitat (LMU) Munich</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siri Houeland di Bari</last_name>
      <phone>+49 89 4400 46458</phone>
      <email>Siri.HouelandDiBari@dzne.de</email>
    </contact>
    <investigator>
      <last_name>Johannes Levin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Center for Neurodegenerative Diseases (DZNE) Tübingen and Hertie-Institute for Clinical Brain Research, University of Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke Kuder-Buletta</last_name>
      <phone>+49-(0)7071-2987584</phone>
      <email>Elke.Kuder-Buletta@dzne.de</email>
    </contact>
    <investigator>
      <last_name>Mathias Jucker, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niigata University</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aki Araki</last_name>
      <email>araki-aki@bri.niigata-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Takeshi Ikeuchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka City University</name>
      <address>
        <city>Osaka City</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Tokyo University</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akemi Nagamatsu</last_name>
      <email>akm77-tky@umin.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Yoshiki Niimi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-Gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jee Hoon Roh, MD, PhD</last_name>
      <phone>82-2-3010-3443</phone>
      <email>roh@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Jae Hong Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Neurología y Neurocirugía &quot;Manuel Velasco Suarez&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>14269</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriela Rojas de la Torre, MS, MA</last_name>
      <email>gabriella.delatorre.1066@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Luisa Sosa Ortiz, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erika Mariana Longoria Ibarrola, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Bosch Capdevila</last_name>
      <email>bbosch@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Raquel Sanchea del Valle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology, Queen Square</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Douglas, RN MPhil.</last_name>
      <phone>0044 (0)845 155 5000</phone>
      <phone_ext>723560</phone_ext>
      <email>jdouglas@drc.ion.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Martin Rossor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://dian.wustl.edu/</url>
    <description>DIAN Website</description>
  </link>
  <link>
    <url>http://knightadrc.wustl.edu/</url>
    <description>Washington University St. Louis Knight Alzheimer's Disease Research Center</description>
  </link>
  <reference>
    <citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006 Aug 8;67(3):446-52.</citation>
    <PMID>16894106</PMID>
  </reference>
  <reference>
    <citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.</citation>
    <PMID>17210801</PMID>
  </reference>
  <reference>
    <citation>Godbolt AK, Cipolotti L, Anderson VM, Archer H, Janssen JC, Price S, Rossor MN, Fox NC. A decade of pre-diagnostic assessment in a case of familial Alzheimer's disease: tracking progression from asymptomatic to MCI and dementia. Neurocase. 2005 Feb;11(1):56-64.</citation>
    <PMID>15804925</PMID>
  </reference>
  <reference>
    <citation>Morris JC, McKeel DW Jr, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991 Apr;41(4):469-78.</citation>
    <PMID>2011242</PMID>
  </reference>
  <reference>
    <citation>Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Xiong C, Grant E, Storandt M, Morris JC. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol. 2005 May;62(5):758-65.</citation>
    <PMID>15883263</PMID>
  </reference>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>March 25, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <last_update_submitted>February 9, 2022</last_update_submitted>
  <last_update_submitted_qc>February 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>antecedent biomarkers</keyword>
  <keyword>Amyloid Precursor Protein (APP) mutation</keyword>
  <keyword>presenilin I (PS1) mutation</keyword>
  <keyword>presenilin 2 (PS2) mutation</keyword>
  <keyword>Autosomal Dominant Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

